TEVA
Price
$18.34
Change
-$0.02 (-0.11%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
21.66B
41 days until earnings call
VTRS
Price
$9.52
Change
+$0.03 (+0.32%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
11.06B
45 days until earnings call
Interact to see
Advertisement

TEVA vs VTRS

Header iconTEVA vs VTRS Comparison
Open Charts TEVA vs VTRSBanner chart's image
Teva Pharmaceutical Industries
Price$18.34
Change-$0.02 (-0.11%)
Volume$119.32K
Capitalization21.66B
Viatris
Price$9.52
Change+$0.03 (+0.32%)
Volume$166.59K
Capitalization11.06B
TEVA vs VTRS Comparison Chart in %
Loading...
TEVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
TEVA vs. VTRS commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TEVA is a Buy and VTRS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (TEVA: $18.36 vs. VTRS: $9.49)
Brand notoriety: TEVA: Notable vs. VTRS: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: TEVA: 91% vs. VTRS: 77%
Market capitalization -- TEVA: $21.66B vs. VTRS: $11.06B
TEVA [@Pharmaceuticals: Generic] is valued at $21.66B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $11.06B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TEVA’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • TEVA’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, TEVA is a better buy in the long-term than VTRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TEVA’s TA Score shows that 4 TA indicator(s) are bullish while VTRS’s TA Score has 5 bullish TA indicator(s).

  • TEVA’s TA Score: 4 bullish, 5 bearish.
  • VTRS’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, both TEVA and VTRS are a bad buy in the short-term.

Price Growth

TEVA (@Pharmaceuticals: Generic) experienced а -0.49% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was -3.75% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.63%. For the same industry, the average monthly price growth was +25.30%, and the average quarterly price growth was +68.10%.

Reported Earning Dates

TEVA is expected to report earnings on Nov 06, 2025.

VTRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.63% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TEVA($21.7B) has a higher market cap than VTRS($11.1B). TEVA YTD gains are higher at: -16.697 vs. VTRS (-20.821). TEVA has higher annual earnings (EBITDA): 1.9B vs. VTRS (-493.3M). TEVA has more cash in the bank: 2.16B vs. VTRS (809M). VTRS has less debt than TEVA: VTRS (14.8B) vs TEVA (17.5B). TEVA has higher revenues than VTRS: TEVA (16.6B) vs VTRS (14.1B).
TEVAVTRSTEVA / VTRS
Capitalization21.7B11.1B195%
EBITDA1.9B-493.3M-385%
Gain YTD-16.697-20.82180%
P/E RatioN/A236.20-
Revenue16.6B14.1B118%
Total Cash2.16B809M267%
Total Debt17.5B14.8B118%
FUNDAMENTALS RATINGS
TEVA vs VTRS: Fundamental Ratings
TEVA
VTRS
OUTLOOK RATING
1..100
7867
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
48100
SMR RATING
1..100
9396
PRICE GROWTH RATING
1..100
4658
P/E GROWTH RATING
1..100
111
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is somewhat better than the same rating for TEVA (74) in the Pharmaceuticals Generic industry. This means that VTRS’s stock grew somewhat faster than TEVA’s over the last 12 months.

TEVA's Profit vs Risk Rating (48) in the Pharmaceuticals Generic industry is somewhat better than the same rating for VTRS (100) in the null industry. This means that TEVA’s stock grew somewhat faster than VTRS’s over the last 12 months.

TEVA's SMR Rating (93) in the Pharmaceuticals Generic industry is in the same range as VTRS (96) in the null industry. This means that TEVA’s stock grew similarly to VTRS’s over the last 12 months.

TEVA's Price Growth Rating (46) in the Pharmaceuticals Generic industry is in the same range as VTRS (58) in the null industry. This means that TEVA’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is in the same range as TEVA (11) in the Pharmaceuticals Generic industry. This means that VTRS’s stock grew similarly to TEVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
TEVAVTRS
RSI
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
57%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
57%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
63%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 8 days ago
69%
Declines
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 4 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
59%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
TEVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DOG24.550.11
+0.45%
ProShares Short Dow30
PBAP28.34N/A
N/A
PGIM S&P 500 Buffer 20 ETF - Apr
WDTE33.60-0.10
-0.29%
Defiance S&P 500 Target 30 Income ETF
HEGD24.65-0.13
-0.51%
Swan Hedged Equity US Large Cap ETF
JAVA68.07-0.35
-0.51%
JPMorgan Active Value ETF

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
-4.72%
AMRX - TEVA
41%
Loosely correlated
-1.13%
VTRS - TEVA
32%
Poorly correlated
-2.27%
ELAN - TEVA
29%
Poorly correlated
+0.91%
NBIX - TEVA
23%
Poorly correlated
-3.94%
OGI - TEVA
23%
Poorly correlated
-3.31%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
-2.27%
ELAN - VTRS
54%
Loosely correlated
+0.91%
ZTS - VTRS
48%
Loosely correlated
-0.38%
AMRX - VTRS
44%
Loosely correlated
-1.13%
EBS - VTRS
43%
Loosely correlated
+5.43%
COLL - VTRS
38%
Loosely correlated
-1.45%
More